Investigation of computed tomography findings of portal hypertension at non-alcoholic fatty liver disease

被引:0
|
作者
Kulali, Fatma [1 ]
Kaya-Tuna, Burcu [1 ]
Semiz-Oysu, Aslihan [1 ]
Kilicoglu, Zeynep Gamze [2 ]
Bukte, Yasar [1 ]
机构
[1] Umraniye Training & Res Hosp, Istanbul, Turkey
[2] Haydarpasa Numune Training & Res Hosp, Istanbul, Turkey
关键词
Hepatosteatosis; Portal hypertension; Fatty liver; Cirrhosis;
D O I
10.1016/j.ejrnm.2016.05.012
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background: Non-alcoholic fatty liver disease (NAFLD) is very common and serious disease. It begins as a simple hepatosteatosis but can progress to cirrhosis. The early detection of portal hypertension (HT) can be helpful in the management of these patients. Aims: To evaluate radiologic findings of portal hypertension at computed tomography (CT) of patients with non-alcoholic fatty liver disease for early diagnosis. Methods and materials: Images of 225 cases who underwent non-enhanced abdominal CT were reviewed. The patients with the difference between hepatic and splenic attenuation (CT L-S) > 10 were enrolled in hepatosteatosis group. The remainings formed control group. The relationship between two groups about diameters of portal and splenic veins, craniocaudal (CC) span of liver, splenic index, caudate lobe/right lobe (C/RL) ratio was analyzed statistically by Mann-Whitney U Test and Student's t-test. Results: Total 213 cases, as hepatosteatosis (n = 149) and control (n = 64) groups, were involved in this study. Liver CC span, splenic index and C/RL ratio between two groups were found to be statistically significant (p < 0.01). Conclusions: The splenic index and C/RL ratio are important findings of portal HT and fibrosis. CT imaging can be beneficial for diagnosis and treatment of NAFLD patients. (C) 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier.
引用
收藏
页码:707 / 710
页数:4
相关论文
共 50 条
  • [1] Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease
    Daher, Saleh
    Cohen, Namma Lev
    Massarwa, Muhammad
    Mahamid, Mahmud
    Nasser, Mira
    Hazou, Wadi
    Oren, Rani
    Safadi, Rifaat
    Khoury, Tawfik
    PLOS ONE, 2018, 13 (11):
  • [2] Portal vein hemodynamics in patients with non-alcoholic fatty liver disease
    Erdogmus, Besir
    Tamer, Ali
    Buyukkaya, Ramazan
    Yazici, Burhan
    Buyukkaya, Ayla
    Korkut, Esin
    Alcelik, Aytekin
    Korkmaz, Ugur
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2008, 215 (01) : 89 - 93
  • [3] Non-alcoholic Fatty Liver Disease
    Tan, Hui-Hui
    Chang, Jason Pik-Eu
    PROCEEDINGS OF SINGAPORE HEALTHCARE, 2010, 19 (01) : 36 - 50
  • [4] Non-alcoholic fatty liver disease
    Smith, Briohny W.
    Adams, Leon A.
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2011, 48 (03) : 97 - 113
  • [5] Non-Alcoholic Fatty Liver Disease
    Engin, Atilla
    OBESITY AND LIPOTOXICITY, 2017, 960 : 443 - 467
  • [6] Non-alcoholic fatty liver disease
    Li, Wenhao
    Alazawi, William
    CLINICAL MEDICINE, 2020, 20 (05) : 509 - 512
  • [7] Mineralocorticoid receptors in non-alcoholic fatty liver disease
    Schreier, Barbara
    Zipprich, Alexander
    Uhlenhaut, Henriette
    Gekle, Michael
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (13) : 3165 - 3177
  • [8] Current treatment of non-alcoholic fatty liver disease
    Paternostro, Rafael
    Trauner, Michael
    JOURNAL OF INTERNAL MEDICINE, 2022, 292 (02) : 190 - 204
  • [9] Non-alcoholic fatty liver disease: a massive problem
    Day, Christopher P.
    CLINICAL MEDICINE, 2011, 11 (02) : 176 - 178
  • [10] Histological assessment of non-alcoholic fatty liver disease
    Huebscher, S. G.
    HISTOPATHOLOGY, 2006, 49 (05) : 450 - 465